drugset / Trial / NCT05184868
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
RandomizedCrossoverQuadruple-blindTreatment
Summary
Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants with type 1 diabetes mellitus (T1DM) during continuous subcutaneous infusion (CSII)
Timeline
- Start
- 2022-01-03
- Primary completion
- 2022-09-09
- Completion
- 2022-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AT247 | Protein / enzyme biologic | 0.02 iu/kg | Subcutaneous |
| Subject | AT247 | Protein / enzyme biologic | 0.15 iu/kg | Subcutaneous |
| Subject | insulin aspart | Protein / enzyme biologic | 0.02 iu/kg | Subcutaneous |
| Subject | insulin aspart | Protein / enzyme biologic | 0.15 iu/kg | Subcutaneous |